Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Argus Research, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.3 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Evaxion A/S
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention Argus Research, the most common co-covered peer. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 1 Finance story that mention Evaxion A/S, all published on August 22, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Evaxion A/S. Shared-story counts are live from our verified record — not editorial picks.
Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Evaxion A/S is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.